Photosynthetic phosphorylation

A brief history of the discovery of photosynthetic phosphorylation by chloroplasts and bacterial chromatophores is presented. Arnon early introduced the terminology of Cyclic and Non-cyclic photophosphorylation and Cyclic and Non-Cyclic electron transport to the processes observed in illuminated chloroplasts. He made major contributions to the elucidation of these processes and stressed their great biological significance. Investigations of the electron transport components of chromatophores have led to the isolation, purification and crystallization of bacterial reaction centers. The development of three-dimensional molecular structures, and the characterization of their electron transfer components have provided a great deal of information about the early reactions of bacterial photosynthesis. The electron transfer schemes presented clearly support the cyclic nature of light-induced electron transfer. Recent developments in the understanding of ATP synthesis in oxidative phosphorylation by mitochondria and in photophosphorylation by chloroplasts and bacterial chromatophores are discussed.Abbreviations ADP, ATP adenosine 5-di- and triphosphates - NADP⁺, NADPH oxidized and reduced Nicotinamide-adenine dinucleotide phosphate - RC reaction center - EPR electron paramagnetic resonance - F₀F₁ ATP-synthase (synthetase) of mitochondria, chloroplasts, and of chromatophores - F₀ membrane portion of ATP-synthase - F₁-ATPase water soluble sector of ATP-synthase     

Estrogen receptor phosphorylation

Estrogen receptor alpha (ERalpha) is phosphorylated on multiple amino acid residues. For example, in response to estradiol binding, human ERalpha is predominately phosphorylated on Ser-118 and to a lesser extent on Ser-104 and Ser-106. In response to activation of the mitogen-activated protein kinase pathway, phosphorylation occurs on Ser-118 and Ser-167. These serine residues are all located within the activation function 1 region of the N-terminal domain of ERalpha. In contrast, activation of protein kinase A increases the phosphorylation of Ser-236, which is located in the DNA-binding domain. The in vivo phosphorylation status of Tyr-537, located in the ligand-binding domain, remains controversial. In this review, I present evidence that these phosphorylations occur, and identify the kinases thought to be responsible. Additionally, the functional importance of ERalpha phosphorylation is discussed.     

Control by phosphorylation

The two examples of phospho and dephospho proteins for which structural data were previously available (glycogen phosphorylase and isocitrate dehydrogenase) demonstrated two different mechanisms for control. In glycogen phosphorylase, activation by phosphorylation results in long-range allosteric changes. In isocitrate dehydrogenase, inhibition by phosphorylation is achieved by an electrostatic blocking mechanism with no conformational changes. During the past year, the structures of the phospho and dephospho forms of two more proteins, the cell cycle protein kinase CDK2 and yeast glycogen phosphorylase, have been determined. The new results highlight the importance of the phosphoamino acids both in the organization of local regions of protein structure through phosphate—arginine interactions and in the promotion of long-range conformational responses.     

Androgen receptor phosphorylation. Regulation and identification of the phosphorylation sites

Activation of signal transduction kinase cascades has been shown to alter androgen receptor (AR) activity. Although it has been suggested that changes in AR phosphorylation might be directly responsible, the basal and regulated phosphorylations of the AR have not been fully determined. We have identified the major sites of AR phosphorylation on ARs expressed in COS-1 cells using a combination of peptide mapping, Edman degradation, and mass spectrometry. We describe the identification of seven AR phosphorylation sites, show that the phosphopeptides seen with exogenously expressed ARs are highly similar to those seen with endogenous ARs in LNCaP cells and show that specific agonists differentially regulate the phosphorylation state of endogenous ARs in LNCaP prostate cancer cells. Treatment of LNCaP cells with the synthetic androgen, R1881, elevates phosphorylation of serines 16, 81, 256, 308, 424, and 650. Ser-94 appears constitutively phosphorylated. Forskolin, epidermal growth factor, and phorbol 12-myristate 13-acetate increase the phosphorylation of Ser-650. The kinetics of phosphorylation of most sites in response to hormone or forskolin is temporally delayed, reaching a maximum at 2 h post-stimulation. The exception is Ser-81, which continues to display increasing phosphorylation at 6 h. These data provide a basis for analyzing mechanisms of cross-talk between growth factor signaling and androgen in prostate development, physiology, and cancer.     

CCK receptor phosphorylation exposes regulatory domains affecting phosphorylation and receptor trafficking

Agonist-stimulatedphosphorylation of guanine nucleotide-binding protein (Gprotein)-coupled receptors has been recognized as an importantmechanism for desensitization by interfering with coupling of theactivated receptor with its G protein. We recently described a mutantof the CCK receptor that modified two of five key sites ofphosphorylation (S260,264A) and eliminated agonist-stimulated receptorphosphorylation, despite normal ligand binding and signaling (20). As expected, this nonphosphorylated mutant hadimpaired rapid desensitization but was ultimately able to bedesensitized by normal receptor internalization. Here we demonstratethat this mutant receptor is also defective in resensitization, withabnormal recycling to the cell surface. To explore this, anotherreceptor mutant was prepared, replacing the same serines withaspartates to mimic the charge of serine-phosphate (S260,264D). Thismutant was expressed in a Chinese hamster ovary cell line and shown to bind CCK normally. It had accelerated kinetics of signaling and desensitization and was phosphorylated in response to agonist occupation, with all other normal sites of phosphorylation modified. Itwas internalized like wild-type receptors and was resensitized andtrafficked normally. This provides evidence for an additional importantfunction for phosphorylation of G protein-coupled receptors. Phosphorylation may induce a conformational change in the receptor toexpose other potential sites of phosphorylation and to expose domainsinvolved in the targeting and trafficking of endosomes. Thehierarchical phosphorylation of these sites may play a key role inreceptor regulation.

     

Frap-dependent serine phosphorylation of IRS-1 inhibits IRS-1 tyrosine phosphorylation

We have previously shown that interferon-alpha (IFN alpha)-dependent tyrosine phosphorylation of insulin receptor substrate-1 (IRS-1) is impaired by serine phosphorylation of IRS-1 due to the reduced ability of serine phosphorylated IRS-1 to serve as a substrate for Janus kinase 1 (JAK1). Here we report that FKBP12-rapamycin-associated protein (FRAP) is a physiologic IRS-1 kinase that blocks IFN alpha signaling by serine phosphorylating IRS-1. We found that both FRAP and insulin-activated p70 S6 kinase (p70(s6k)) serine phosphorylated IRS-1 between residues 511 and 772 (IRS-1(511-772)). Importantly, only FRAP-dependent IRS-1(511-772) serine phosphorylation inhibited by 50% subsequent JAK1-dependent tyrosine phosphorylation of IRS-1. Furthermore, treatment of U266 cells with the FRAP inhibitor rapamycin increased IFN alpha-dependent tyrosine phosphorylation by twofold while reducing constitutive IRS-1 serine phosphorylation within S/T-P motifs by 80%. Taken together, these data indicate that FRAP, but not p70(s6k), is a likely physiologic IRS-1 serine kinase that negatively regulates JAK1-dependent IRS-1 tyrosine phosphorylation and suggests that FRAP may modulate IRS-dependent cytokine signaling.     

Tyrosine phosphorylation modifies protein kinase C delta-dependent phosphorylation of cardiac troponin I

Our study identifies tyrosine phosphorylation as a novel protein kinase Cdelta (PKCdelta) activation mechanism that modifies PKCdelta-dependent phosphorylation of cardiac troponin I (cTnI), a myofilament regulatory protein. PKCdelta phosphorylates cTnI at Ser23/Ser24 when activated by lipid cofactors; Src phosphorylates PKCdelta at Tyr311 and Tyr332 leading to enhanced PKCdelta autophosphorylation at Thr505 (its activation loop) and PKCdelta-dependent cTnI phosphorylation at both Ser23/Ser24 and Thr144. The Src-dependent acquisition of cTnI-Thr144 kinase activity is abrogated by Y311F or T505A substitutions. Treatment of detergent-extracted single cardiomyocytes with lipid-activated PKCdelta induces depressed tension at submaximum but not maximum [Ca2+] as expected for cTnI-Ser23/Ser24 phosphorylation. Treatment of myocytes with Src-activated PKCdelta leads to depressed maximum tension and cross-bridge kinetics, attributable to a dominant effect of cTnI-Thr144 phosphorylation. Our data implicate PKCdelta-Tyr311/Thr505 phosphorylation as dynamically regulated modifications that alter PKCdelta enzymology and allow for stimulus-specific control of cardiac mechanics during growth factor stimulation and oxidative stress.